cbdMD initiates clinical study exploring cannabinoid blend in humans

• cbdMD (YCBD +0.7%) has commenced a preclinical human study with researchers at the University of South Carolina.
• The study will explore the effects of cbdMD’s proprietary broad spectrum cannabinoid blend on sleep, mood, and pain in healthy subjects to further support the efficacy of the Company’s products.
• The studies will also be measuring key safety markers in healthy humans to augment YCBD's safety dossiers for regulatory submissions.
• cbdMD anticipates that these favorable outcomes will be the basis for future drug research and applications by its therapeutics division.